Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shu-Hui Liu

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Scientific Reports|February 23, 2019
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugatesMaria José Costa, Jyothirmayee Kudaravalli, Jing-Tyan Ma, et al.
Breast Cancer Research : BCR|November 13, 2013
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitorsYun-Ju Chen, Ming-Hsin Yeh, Meng-Chieh Yu, et al.
Molecular Cancer Therapeutics|March 6, 2016
Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker DesignMagdalena Dorywalska, Russell Dushin, Ludivine Moine, et al.
Science Bulletin|June 24, 2026
Pancancer pro-angiogenic atlas unravels tumor-educated pericyte-augmented anti-angiogenic resistanceYongqiang Zheng, Hui Sun, Zhe Fu, et al.
Journal of Hematology & Oncology|May 21, 2017
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemiaManoj K Kashyap, Carlos I Amaya-Chanaga, Deepak Kumar, et al.
Scientific Reports|June 12, 2019
Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic CancerGuoyun Zhu, Davide Foletti, Xiaohui Liu, et al.
Scientific Reports|November 9, 2019
Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic CancerGuoyun Zhu, Davide Foletti, Xiaohui Liu, et al.
Cancer Discovery|January 24, 2023
Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung CancerWeining Weng, Tao Meng, Qianqian Zhao, et al.
Plos One|July 11, 2015
Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC EfficacyMagdalena Dorywalska, Pavel Strop, Jody A Melton-Witt, et al.
Bioconjugate Chemistry|February 3, 2015
Effect of attachment site on stability of cleavable antibody drug conjugatesMagdalena Dorywalska, Pavel Strop, Jody A Melton-Witt, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Scientific Reports|February 23, 2019
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugatesMaria José Costa, Jyothirmayee Kudaravalli, Jing-Tyan Ma, et al.
Breast Cancer Research : BCR|November 13, 2013
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitorsYun-Ju Chen, Ming-Hsin Yeh, Meng-Chieh Yu, et al.
Molecular Cancer Therapeutics|March 6, 2016
Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker DesignMagdalena Dorywalska, Russell Dushin, Ludivine Moine, et al.
Science Bulletin|June 24, 2026
Pancancer pro-angiogenic atlas unravels tumor-educated pericyte-augmented anti-angiogenic resistanceYongqiang Zheng, Hui Sun, Zhe Fu, et al.
Journal of Hematology & Oncology|May 21, 2017
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemiaManoj K Kashyap, Carlos I Amaya-Chanaga, Deepak Kumar, et al.
Scientific Reports|June 12, 2019
Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic CancerGuoyun Zhu, Davide Foletti, Xiaohui Liu, et al.
Scientific Reports|November 9, 2019
Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic CancerGuoyun Zhu, Davide Foletti, Xiaohui Liu, et al.
Cancer Discovery|January 24, 2023
Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung CancerWeining Weng, Tao Meng, Qianqian Zhao, et al.
Plos One|July 11, 2015
Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC EfficacyMagdalena Dorywalska, Pavel Strop, Jody A Melton-Witt, et al.
Bioconjugate Chemistry|February 3, 2015
Effect of attachment site on stability of cleavable antibody drug conjugatesMagdalena Dorywalska, Pavel Strop, Jody A Melton-Witt, et al.
Pageof 9